JIMMY LEGROS: Open Payments
NPI 1063419745 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$657 in 27 payments from 10 companies in 2025. Trend: 2023 $266 · 2024 $124 · 2025 $657
Food & beverage: $657
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $203 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $158 |
| ABBVIE INC. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Valinor Pharma, LLC | 3 | $44 |
| Amgen Inc. | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: AIRSUPRA, CAPLYTA, VRAYLAR, REXULTI, Auvelity, FANAPT, MOVANTIK, BREZTRI.
Industry payments across LA — which companies pay providers there.
